LRRK2 mediates haloperidol-induced changes in striatal indirect pathway circuits

Haloperidol is used to manage psychotic symptoms in several neurological disorders through mechanisms that involve antagonism of dopamine D2Rs that are highly expressed in the striatum. Significant side effects of haloperidol, known as extrapyramidal symptoms, lead to motor deficits similar to those seen in Parkinson's disease and present a major challenge in clinical settings. The underlying molecular mechanisms responsible for these side effects remain poorly understood. Parkinson's disease associated LRRK2 kinase has a critical role in striatal physiology and a known link to D2R signaling. Here, we systematically explore convergent signaling of haloperidol and LRRK2.